Annette Juul Vangsted

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 435 citations · Full text

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

Marie K. Brimnes, Annette Juul Vangsted, Lene Meldgaard Knudsen et al. · Scandinavian Journal of Immunology · 2010 · 212 citations

Immunodeficiencies, T-regulatory Cell, Immunology +24

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

Peter Gimsing, Kristina Carlson, Ingemar Turesson et al. · The Lancet Oncology · 2010 · 117 citations · Full text

Bone Disease, Hematological Malignancy, Bone Health +8

Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study

Rasmus Sørrig, Tobias Wirenfeldt Klausen, Morten Salomo et al. · European Journal Of Haematology · 2015 · 68 citations · Full text

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Paul G. Richardson, Suzanne Trudel, Rakesh Popat et al. · New England Journal of Medicine · 2023 · 68 citations · Full text